Clinical Study

S1616- A Phase II Randomized Study Of Nivolumab (Nsc-748726) With Ipilimumab (Nsc-732442) Of Ipilimumab Alone In Advanced Melanoma Patients Refractory To An Anti-Pd1 Or Anti-Pd-L1 Agent

Posted Date: Mar 6, 2020

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology, Skin Cancer
  • Type of Study: Drug

To compare progression free survival (PFS) of patients with advanced melanoma refractory to an anti-PD-1 or anti-PD-L1 agent, treated with combination therapy ipilimumab plus nivolumab versus ipilimumab alone


To Be Eligible: Pathologically Confirmed Melanoma That Is Either Stage Iv Or Unresectable Stage Iii, Progression On Prior Anti-Pd1 Treatment, No Systemic Therapy Within 21 Days, Zubrod Performance Status Of = 2, Active Or Uncontrolled Infection Or Illness Impacting Study, No Other Malignancy Within 2 Years Ex Nonmelanoma Skin Cancer And In Situ Cervical,


Melanoma, Skin Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.